Swedish Orphan Biovitrum AB

About Us

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

Contacts

Visiting address

Norra Stationsgatan 93A, Sweden

+46 8 697 20 00
info@sobi.com

Gerard Tobin

Head of Investor Relations

gerard.tobin@sobi.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth

Tue, Nov 13, 2018 08:00 CET

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth

Subscribe